Multiplex Soluble Biomarker Analysis from Pleural Effusion

Joman Javadi1, Katalin Dobra1,2, Anders Hjerpe2

  • 1Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Huddinge University Hospital, SE-14186 Stockholm, Sweden.

Biomolecules
|August 1, 2020
PubMed

Insights

Malignant pleural mesothelioma (MPM) diagnosis can be improved using specific biomarkers. Shed Syndecan-1 (SDC-1) and VEGF show prognostic value, while MMP-7, SDC-1, Mesothelin, and Galectin-1 aid in diagnosis.

Area of Science:

  • Oncology
  • Biomarker Discovery
  • Pleural Diseases

Background:

  • Malignant pleural mesothelioma (MPM) is an aggressive cancer linked to asbestos exposure with poor prognosis.
  • Current diagnostic methods for MPM include histopathology, cytopathology, and immunohistochemistry.
  • Identifying reliable diagnostic and prognostic biomarkers for MPM remains a clinical challenge.

Purpose of the Study:

  • To evaluate soluble angiogenesis-related molecules as potential diagnostic and prognostic biomarkers for MPM.
  • To compare biomarker levels in MPM effusions against adenocarcinoma and benign effusions.

Main Methods:

  • Analyzed 10 angiogenesis-related analytes (Angiopoietin-1, HGF, MMP-7, Osteopontin, TIMP-1, Galectin, Mesothelin, NRG1-b1, SDC-1, VEGF) in pleural effusions from 42 MPM, 36 adenocarcinoma, and 40 benign cases.
  • Utilized Luminex multiplex assay for simultaneous quantification of multiple analytes.

Main Results:

  • MMP-7 and shed SDC-1 were lower, while Mesothelin and Galectin-1 were higher in MPM vs. adenocarcinoma effusions.
  • Galectin-1, HGF, Mesothelin, MMP-7, Osteopontin, shed SDC-1, NRG1-β1, VEGF, and TIMP-1 were significantly higher in MPM vs. benign effusions.
  • Shed SDC-1 and VEGF demonstrated prognostic value in MPM patients.

Conclusions:

  • MMP-7, shed SDC-1, Mesothelin, and Galectin-1 show promise as diagnostic markers for MPM.
  • VEGF and shed SDC-1 are potential prognostic markers for MPM.
  • These biomarkers could improve the diagnostic accuracy and prognostic assessment of malignant pleural mesothelioma.